

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Oliver Bruestle	Art Unit:	1632	
Serial No.:	09/581,890	Examiner:	Falk, Anne Marie	
Filing Date:	August 28, 2000	Conf. No.:	7106	
Title:	NEURAL PRECURSOR CELLS, METHOD FOR THE PRODUCTION AND USE THEREOF IN NEURAL DEFECT THERAPY		Cust. No.:	23483

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.
Date: 20 Oct 2004 By: Stephanie R. Douglas
Stephanie R. Douglas

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. § 1.97(c), Applicant and his legal representatives hereby make of record the following references which are known by them and considered warranting disclosure under 37 C.F.R. § 1.56. The best available copy of the references cited on the attached form PTO-1449 are submitted herewith.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no


other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicant understands that the Examiner will make an independent evaluation of the cited publications.

As this Supplemental Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(c), please charge Deposit Account No. 08-0219 the \$180.00 fee for this submission.

No other fees are believed to be due with this submission. However, please charge any underpayment or credit any overpayment to Deposit Account No. 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,



Ann-Louise Kerner, Ph.D.
Reg. No. 33,523

October 20, 2004
HALE AND DORR LLP
60 State Street
Boston, MA 02109
Tel: (617) 526-6000
Fax: (617) 526-5000

Subt. For, PTO-1449				Docket Number 107070-113 VOS-012		Application Number 09/581,890	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Bruestle			
				Filing Date 8/28/2000		Group Art Unit 1632	
Sheet	1	OF	1				

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	97/16534	5/9/1997	WO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
	A1	Roach, et al., "A New Embryonic Stem Cell Line from DBA/1lacJ Mice Allows Genetic Modification in a Murine Model of Human Inflammation", Experimental Cell Research, 221:520-525 (1995)
	A2	
	A3	
	A4	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	